In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Myriad Genetics, Inc (NASDAQ: MYGN) closed the day trading at $14.88 down -1.65% from the previous closing price of $15.13. In other words, the price has decreased by -$1.65 from its previous closing price. On the day, 1.06 million shares were traded. MYGN stock price reached its highest trading level at $15.24 during the session, while it also had its lowest trading level at $14.6501.
Ratios:
For a better understanding of MYGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on Dec-10-24, Downgraded its rating to Market Perform and sets its target price to $21 from $30 previously.
On September 19, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $32.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $35.Wells Fargo initiated its Overweight rating on August 28, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1354603776 and an Enterprise Value of 1397804160. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.52 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 1.697 whereas that against EBITDA is -41.233.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $14.34. The 50-Day Moving Average of the stock is -25.61%, while the 200-Day Moving Average is calculated to be -35.52%.
Shares Statistics:
Over the past 3-months, MYGN traded about 805.41K shares per day on average, while over the past 10 days, MYGN traded about 798240 shares per day. A total of 91.00M shares are outstanding, with a floating share count of 87.61M. Insiders hold about 3.76% of the company’s shares, while institutions hold 100.22% stake in the company. Shares short for MYGN as of 1731628800 were 3694325 with a Short Ratio of 4.59, compared to 1728950400 on 4494424. Therefore, it implies a Short% of Shares Outstanding of 3694325 and a Short% of Float of 5.6799997.
Earnings Estimates
The stock of Myriad Genetics, Inc (MYGN) is currently being evaluated by 14.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.0, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.17 and $0.12 for the fiscal current year, implying an average EPS of $0.13. EPS for the following year is $0.13, with 14.0 analysts recommending between $0.29 and -$0.18.
Revenue Estimates
13 analysts predict $213.38M in revenue for the current quarter. It ranges from a high estimate of $218M to a low estimate of $210.7M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $196.6MFor the next quarter, 13 analysts are estimating revenue of $212.59M. There is a high estimate of $217.5M for the next quarter, whereas the lowest estimate is $207.4M.
A total of 14 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $845M, while the lowest revenue estimate was $837.7M, resulting in an average revenue estimate of $840.58M. In the same quarter a year ago, actual revenue was $753.2MBased on 14 analysts’ estimates, the company’s revenue will be $883.34M in the next fiscal year. The high estimate is $896.85M and the low estimate is $861.32M.
